To access the appropriate site, please select from the following options:

If you are a patient/carer/member of the public or healthcare professional looking for information on CRYSVITA, please click the corresponding link.

Otherwise, if you would like information on X-linked hypophosphataemia, please click on the last link.

Information on X-linked hypophosphataemia
Please note all three websites accessed via these links are developed and funded by Kyowa Kirin International.
You are about to leave a Kyowa Kirin website.

The site you are about to go to is not under the control of Kyowa Kirin International. Kyowa Kirin International is not responsible for the content of any such site or any further link from such site.

Are you sure you want to continue?

Yes
Crysvita.eu
Adult Dosing Factsheet Paediatric Dosing Table TmP/GFR Factsheet Prescribing Information Patient Site
  • What is XLH?
    • Causes of XLH
    • Clinical manifestations
    • Prevalence
    • Hereditary pattern
  • How does CRYSVITA work?
    • FGF23 and XLH
    • CRYSVITA mode of action
    • Phosphate homeostasis
  • Why CRYSVITA?
    • Paediatric Studies
    • Adult Studies
  • Starting CRYSVITA
    • Dosing
    • Administration
    • Monitoring
    • Storage
  • Resources
    • Downloadable materials
    • Webinars
    • Publications of interest
    • Key facts
    • Useful websites
Prescribing Information

XLH is a rare, hereditary*, progressive and life-long phosphate wasting disorder, caused by mutations in the PHEX gene that leads to excess FGF23¹⁻⁴

  • Causes of XLH
  • Clinical manifestations
  • Prevalence
  • Hereditary pattern

XLH is characterised by chronic hypophosphataemia due to increased FGF23 levels2,4

Phosphate is critical to many biological functions.5 Disruption of normal phosphate homeostasis is associated with severe complications and has detrimental effects on overall health.5

In XLH, excessive levels of FGF23 decrease renal phosphate reabsorption and active vitamin D (1,25[OH]2D) production, which increases urinary phosphate excretion and reduces intestinal phosphate absorption, respectively; this leads to low serum phosphate levels.2,6

Excess FGF23 leads to chronic hypophosphataemia resulting in impaired bone mineralisation, severely affecting the growth and development of children with XLH2,6 and leading to osteomalacia in adults with XLH.8

Learn more about the role of FGF23 in XLH and CRYSVITA’s mechanism of action

XLH is a multisystemic disease that impacts bone, muscle and dentition4

The clinical manifestations of XLH develop very early in life and usually become apparent during the first 2 years typically presenting as lower limb deformities (e.g. bowing of the legs).3,4

In children, XLH causes rickets, progressive lower limb deformity, impaired growth, poor dental health and, in some cases, skull deformities, but the signs and symptoms can vary in severity.6

In adults with XLH, bone, joint and cartilage deficits include pseudofractures/fractures, early-onset osteoarthritis, osteophyte formation, enthesopathies and spinal stenosis. Adults can experience dental impairments, sensorineural hearing loss, tinnitus and vertigo.6

People with XLH commonly exhibit impairments in mobility and physical function, bone and joint pain, fatigue as well as emotional and social detriments throughout life.4,8

The clinical manifestations of XLH vary in presentation and severity, and can impair physical function and
quality of life6,8,9

XLH is a progressive, life-long disease and clinical manifestations accumulate over time. Adults with XLH present with clinical manifestations that derive from childhood as well as new complications that occur later in life.8

XLH is a rare disease

In the EU, a disease is defined as rare when it affects fewer than 1 in 2,000 people.10

XLH is estimated to affect approximately 1 in 20,000– 1 in 60,000 people.1,6,7
Due to its rarity, there is often a delay in diagnosis and treatment.4

XLH is inherited in an X-linked dominant pattern; however, 20–30% of cases arise from spontaneous mutations11-13

XLH is caused by mutations in the PHEX gene.4 In most cases, XLH is inherited in an X-linked dominant pattern.11

Hereditary pattern of XLH

Click the father or mother below to reveal the ratio of affected sons and daughters with an affected parent.
(dark blue indicates affected individual).

Genetic analysis can help confirm a diagnosis of XLH and identify family members who may be at risk.4

See how CRYSVITA can improve mobility, stiffness, functional disability, fatigue and pain in people with XLH.
*In approximately 20–30% of cases, XLH occurs spontaneously and there is no family history.12,13
1. Beck-Nielsen SS, et al. Eur J Endocrinol. 2009;160:491–97. 2. Martin A & Quarles LD. Adv Exp Med Biol. 2012;728:65–83. 3. Carpenter TO, et al. J Bone Miner Res. 2011;26:1381–88. 4. Haffner D, et al. Nat Rev Nephrol. 2019;15:435–55. 5. Penido MGMG & Alon US. Pediatr Nephrol. 2012;27:2039–48. 6. Beck-Nielsen SS, et al. Orphanet J Rare Dis. 2019;14:58. 7. Rafaelsen S, et al. Eur J Endocrinol. 2016;174:125–36. 8. Skrinar A, et al. J Endocr Soc. 2019;3:1321–34. 9. Linglart A, et al. Endocr Connect. 2014;3:R13–30. 10. European Commission. Rare Diseases. Available at: https://ec.europa.eu/health/non_communicable_diseases/rare_diseases_en. Accessed: January 2021. 11. Whyte MP, et al. J Clin Endocrinol Metab. 1996;81:4075–80. 12. Rajah J, et al. Eur J Pediatr. 2011;170:1089-96. 13. Dixon PH, et al. J Clin Endocrinol Metab. 1998;83:3615–23.
Kyowa Kirin Logo

Website developed and funded by Kyowa Kirin International. © 2019 Kyowa Kirin International Plc. All rights reserved.
CRYSVITA® is a registered trademark of Kyowa Kirin Co., Ltd.
March 2021 KKI/INT/BUR/0896

  • Abbreviations
  • Contact Us
  • Cookies
  • Privacy Notice
  • Terms of Use

This website uses analytic cookies for content measurement and to remember your preferences. By clicking Accept you agree to the use of cookies on this site. For more details about how we use cookies visit the Cookies page.